AstraZeneca's SAPHNELO gets positive EU opinion

TL;DR

EU panel backs AstraZeneca's new asthma drug formulation - big win for patients!

AI Summary

AstraZeneca PLC announced on October 20, 2025, that it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding its subcutaneous formulation of SAPHNELO (benralizumab). This positive opinion is a significant step towards potential approval in the European Union for the treatment of severe eosinophilic asthma.

Why It Matters

This positive opinion from the CHMP could lead to broader access to a new treatment option for patients with severe eosinophilic asthma in the European Union, potentially improving disease management and patient outcomes.

Risk Assessment

Risk Level: low — The filing is an informational report on a positive regulatory opinion, not a financial event with immediate market-moving risk.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant
• SAPHNELO (drug) — Product mentioned
• benralizumab (drug) — Active ingredient of SAPHNELO
• European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) (company) — Regulatory body
• October 20, 2025 (date) — Date of announcement

FAQ

From the Filing

0001654954-25-011943.txt : 20251020 0001654954-25-011943.hdr.sgml : 20251020 20251020064754 ACCESSION NUMBER: 0001654954-25-011943 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251020 FILED AS OF DATE: 20251020 DATE AS OF CHANGE: 20251020 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251402283 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a9156d.htm POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO a9156d FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of October 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________           AstraZeneca PLC   INDEX TO EXHIBITS     1. Positive CHMP opinion for subcutaneous Saphnelo     20 October 2025   Saphnelo   subcutaneous self-administration recommended for approval in EU by CHMP for systemic lupus erythematosus   Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration   AstraZeneca's  Saphnelo  (anifrolumab) has been recommended for approval in the European Union (EU) as a self-administered once-weekly pre-filled pen for adult patients with systemic lupus erythematosus (SLE) on top of standard therapy.   The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on interim results from the Phase III TULIP-SC trial, which showed that subcutaneous (SC) administration of  Saphnelo  led to a statistically significant and clinically meaningful reduction in disease activity compared to placebo in participants with moderate to severe, active, autoantibody-positive SLE while receiving standard therapy. 1,2  The safety profile observed was consistent with the known clinical profile of  Saphnelo  administered as an intravenous (IV) infusion. 3-5   Professor Thomas Dörner, Rheumatologist and Professor of Rheumatology and Hemostaseology at Charité University Hospital, Berlin, Germany and investigator of the TULIP-SC trial said: "The positive recommendation